Clinical applications of adoptive natural killer cell immunotherapy for cancer: Current status and future prospects

Onkologie

Volumn 33, Issue 7, 2010, Pages 389-395

  Guo, Hongfeng ^a   Qian, Xifeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Natural killer cells, alloreactivity

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; DONOR SELECTION; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HLA SYSTEM; HUMAN; INFUSION; NATURAL KILLER CELL; REVIEW; STEM CELL TRANSPLANTATION;

FORECASTING; GRAFT VS HOST REACTION; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKEMIA; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL;

EID: 77954510409     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315698     Document Type: Review

References (62)

1. Bryceson YT, March ME, Ljunggren HG, Long EO: Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91.
2. Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-2438.
3. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187-376.
4. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935-1947.
5. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
6. Sutlu T, Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009;266:154-181.
7. Colonna M, Samaridis J: Cloning of immunoglobulin- superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-408.
8. Yokoyama WM: What goes up must come down: the emerging spectrum of inhibitory receptors. J Exp Med 1997;186:1803-1808.
9. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-342.
10. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713.
11. Jonsson AH, Yokoyama WM: Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009;101:27-79.
12. Brodin P, Lakshmikanth T, Johansson S, Karre K, Hoglund P: The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009;113:2434-2441.
13. Houchins JP, Yabe T, McSherry C, Bach FH: DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-1020.
14. Sobanov Y, Glienke J, Brostjan C, Lehrach H, Francis F, Hofer E: Linkage of the NKG2 and CD94 receptor genes to D12S77 in the human natural killer gene complex. Immunogenetics 1999;49:99-105.
15. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
16. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L: Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086.
17. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L: Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000;21:228-234.
18. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055-1060.
19. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A: Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-1516.
20. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-1503.
21. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C: Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One 2007;2:e1339.
22. Chiorean EG, Miller JS: The biology of natural killer cells and implications for therapy of human disease. J Hematotherapy and Stem Cell Res 2001;10:451-463.
23. Maki G, Krystal G, Dougherty G, Takei F, Klingemann HG: Induction of sensitivity to NKmediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 1998;12:1565-1572.
24. Rosenberg SA, Lotze MT, Muul L, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT: Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
25. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-484.
26. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA: Adoptive cellular therapy. Semin Oncol 2000;27: 221-233.
27. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH: Phase II trials of highdose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 1994;16: 216-223.
28. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF: Phase III randomized trial of interleukin-2 with or without lymphokineactivated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76:824-832.
29. Kimura H, Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-49.
30. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW: Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin- like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004;104:170-177.
31. Richards J, McNally B, Fang XF, Caligiuri MA, Zheng P, and Liu Y: Tumor growth decreases NK and B cells as will as common lymphoid progenitor. PLos ONE 2008;3:e3180.
32. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
33. Ljunggren HG, Kärre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
34. Miller HC, Cudkowicz G: Immunologic memory cells of bone marrow origin. Increased burst size of specific immunocyte precursors. J Exp Med 1972; 135:1028-1036.
35. Yu YY, George T, Dorfman JR, Roland J, Kumar V, Bennett M: The role of Ly49A and 5E6 (Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 1996;4:467-476.
36. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer call alloreactivity in mismatched hematopoietic transplants. Science 2002;295: 2097-2100.
37. Kärre K: A perfect mismatch. Science 2002;295: 2029-2031.
38. Velardi A, Ruggeri L, Alessandro, Moretta, Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002;23:438-444.
39. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-440.
40. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002;100:3825-3827.
41. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM; KIR Study Group, Center for International Blood and Marrow Transplantation Research: The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006;12:876-884.
42. Bornhauser M, Schwerdtfeger R, Martin H, Hertenstein B, Schwerdtfeger R, Martin H, Stelljes M, Hegenbart U, Schäfer-Eckart K, Füssel M, Wiedemann B, Thiede C, Kienast J, Baurmann H, Ganser A, Kolb HJ, Ehninger G: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004;103:2860-2861.
43. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, Yamamoto K, Maruya E, Akatsuka Y, Onizuka M, Sakamaki H, Sao H, Ogawa S, Kato S, Juji T, Sasazuki T, Kodera Y; Japan Marrow Donor Program: Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007;13:315-328.
44. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-819.
45. Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura- Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y, Morishima Y; Japan Marrow Donor Program: Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligandmismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008;14:75-87.
46. Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R, Biersack H, Grosse- Wilde H, Beelen DW: Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005;79:1741-1747.
47. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H: Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the longterm antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005;105:2594-2600.
48. Ruggeri L, Aversa F, Martelli MF, Velardi A: Allogenic haploidentical transplantation and natural killer cell recognition of missing self. Immunol Rev 2006;214:202-218. (Pubitemid 44707912)
49. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P: Human diversity in killer-cell inhibitory receptor genes. Immunity 1997;7:753-763.
50. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R: Determinant of anti-leukemia effects of allogeneic NK cells. J Immunol 2004;172:644-650.
51. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F: Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008;143:641-653.
52. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-3057.
53. Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D: IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004;33:261-266. (Pubitemid 39446496)
54. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, Favre G, Gratwohl A: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004;18:1835-1838.
55. Brand JM, Meller B, Von Hof K, Luhm J, Bähre M, Kirchner H, Frohn C: Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev 2004;13:307-314.
56. Tonn T, Becker S, Esser R, Schwabe D, Seifried E: Adoptive cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001;10:535-544. (Pubitemid 32756192)
57. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H: Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008;10:625-632.
58. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W: Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002;100:1265-1273.
59. Imai C, Iwamoto S, Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-383.
60. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, SuVredini D, Berg M, Childs R: Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006;66:7317-7325.
61. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-4267.
62. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW: Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxici ty in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007; 13:2392-2399.